Stanford Medicine Center for Cancer Cell Therapy
The Stanford Center for Cancer Cell Therapy is a world-class research program that is delivering life saving therapies to adult and pediatric cancer patients
Our impact has been most significant for B-Cell lymphoma malignancies, where CAR T cell therapy has become an FDA approved standard of care. We are now expanding in cell therapies for melanoma, advanced solid tumors, inoperable gliomas of the spine and brainstem, and refractory lymphoma.
Our ultimate goal is to drive the high-risk, high-reward research that fuels the development of groundbreaking cell therapies for patients with currently incurable cancers.
News
– Stanford Medicine NewsCell therapy fights lethal childhood brain cancer in Stanford Medicine trial
CAR-T cells show promise against pediatric diffuse midline gliomas, brain and spinal cord tumors that are among the deadliest cancers, a Stanford Medicine trial found.
– Stanford Cancer InstituteGroundbreaking Stanford cancer treatment receives important FDA designation
A promising Stanford Medicine treatment for deadly pediatric brain and spinal cord cancers received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration to expedite the approval process. By expediting approval, more children will be able to benefit from the treatment sooner.